• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Cardinal Health Inc.

    8/14/25 5:06:21 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email
    8-K
    CARDINAL HEALTH INC false 0000721371 0000721371 2025-08-13 2025-08-13
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 13, 2025

     

     

    Cardinal Health, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Ohio   1-11373   31-0958666

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    7000 Cardinal Place, Dublin, Ohio 43017

    (Address of Principal Executive Offices) (Zip Code)

    (614) 757-5000

    (Registrant’s telephone number, including area code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common shares (without par value)   CAH   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    ITEM 8.01

    Other Events.

    On August 13, 2025, Cardinal Health, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein, for the sale by the Company of $600,000,000 aggregate principal amount of its 4.500% Notes due 2030 and $400,000,000 aggregate principal amount of its 5.150% Notes due 2035. The offering was made pursuant to the Company’s effective registration statement on Form S-3ASR (Registration Statement No. 333-289513) previously filed with the Securities and Exchange Commission.

    A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing summary of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to full text of the Underwriting Agreement.

     

    ITEM 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    Number.

       Description
    1.1    Underwriting Agreement, dated as of August 13, 2025, among Cardinal Health, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        CARDINAL HEALTH, INC.
    Date: August 14, 2025     By:  

    /s/ Aaron E. Alt

        Name:   Aaron E. Alt
        Title:   Chief Financial Officer
    Get the next $CAH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAH

    DatePrice TargetRatingAnalyst
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    12/4/2024$139.00Outperform
    Mizuho
    2/26/2024$125.00Outperform
    Leerink Partners
    More analyst ratings

    $CAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Information Officer Greene Michelle D. was granted 16,362 shares, increasing direct ownership by 88% to 34,968 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    8/12/25 4:28:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    CEO, PSS Segment Weitzman Deborah was granted 39,100 shares, increasing direct ownership by 80% to 88,229 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    8/12/25 4:19:07 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Chief Human Resources Officer Snow Ola M was granted 31,813 shares, increasing direct ownership by 135% to 55,351 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    8/12/25 4:17:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

    8/15/25 4:40:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

    Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expirationFourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08Fiscal Year 2025 adjusted free cash flow was $2.5 billionFiscal year 2026 non-GAAP EPS guidance2 raised to $9.30 to $9.50, from $9.10 to $9.30Company announces the acquisition of Solaris Health, the country's leading urology MSODUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported fourth quarter fiscal year

    8/12/25 6:55:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health announces the addition of Solaris Health, the country's leading urology MSO, to The Specialty Alliance

    Adds over 750 providers to Cardinal Health's multi-specialty MSO platform, The Specialty AllianceJoins with recent urology acquisitions to bolster The Specialty Alliance's leadership in the urology therapeutic areaCardinal Health MSO platforms reach ~3,000 providers in 32 states upon transaction close DUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced that The Specialty Alliance, its multi-specialty management services organization (MSO) platform, has entered into a definitive agreement to acquire Solaris Health, the country's leading urology MSO, from Lee Equity Partners and Solaris Health physician owners.

    8/12/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Carlisle Companies Announces Leadership Appointments

    Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

    5/16/25 4:05:00 PM ET
    $CAH
    $CSL
    $SUM
    Other Pharmaceuticals
    Health Care
    Specialty Chemicals
    Industrials

    Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    3/10/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Financials

    Live finance-specific insights

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

    8/15/25 4:40:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

    Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expirationFourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08Fiscal Year 2025 adjusted free cash flow was $2.5 billionFiscal year 2026 non-GAAP EPS guidance2 raised to $9.30 to $9.50, from $9.10 to $9.30Company announces the acquisition of Solaris Health, the country's leading urology MSODUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported fourth quarter fiscal year

    8/12/25 6:55:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2025, to shareholders of record at the close of business on July 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an op

    5/5/25 5:30:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    SEC Filings

    View All

    SEC Form 8-K filed by Cardinal Health Inc.

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    8/14/25 5:06:21 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form FWP filed by Cardinal Health Inc.

    FWP - CARDINAL HEALTH INC (0000721371) (Subject)

    8/13/25 4:44:29 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form 424B3 filed by Cardinal Health Inc.

    424B3 - CARDINAL HEALTH INC (0000721371) (Filer)

    8/13/25 8:51:32 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cardinal Health upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

    6/3/25 7:24:57 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by Jefferies with a new price target

    Jefferies upgraded Cardinal Health from Hold to Buy and set a new price target of $150.00 from $140.00 previously

    2/5/25 7:09:45 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by TD Cowen with a new price target

    TD Cowen upgraded Cardinal Health from Hold to Buy and set a new price target of $144.00 from $130.00 previously

    1/8/25 7:36:58 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/13/24 5:01:02 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    1/30/24 1:39:03 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/14/23 12:37:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care